<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614936</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A00888-35</org_study_id>
    <secondary_id>2013/1962</secondary_id>
    <nct_id>NCT03614936</nct_id>
  </id_info>
  <brief_title>Study of a Simplified Geriatric Evaluation Performed by Oncologists Prior to Cancer Treatment by Radiotherapy or Chemotherapy in Subjects Aged 70 Years or Older With Inoperable Squamous Cell Cancer of the Head and Neck</brief_title>
  <acronym>ELAN-ONCOVAL</acronym>
  <official_title>Study of a Simplified Geriatric Evaluation Performed by Oncologists Prior to Cancer Treatment by Radiotherapy or Chemotherapy in Subjects Aged 70 Years or Older With Inoperable Squamous Cell Cancer of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use by Oncologists of Validated Geriatric Assessment Tools: G8 Screening Test and Certain
      Tests for Thorough Geriatric Evaluation
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 11, 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Completion rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Rate of completion of each of the geriatric fragility test questionnaires and the G8 questionnaire and duration of the geriatric evaluation performed by the oncologist</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Inoperable Squamous Cell Cancer of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Inoperable squamous cell cancer of the head and neck</arm_group_label>
    <description>patients 70 years of age or older with ENT carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Geriatric Screening Test G8</intervention_name>
    <description>Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).</description>
    <arm_group_label>Inoperable squamous cell cancer of the head and neck</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Geriatric fragility test GERICO</intervention_name>
    <description>GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:
the socio-cultural evaluation scale,
the ADL autonomy questionnaire,
assessment of locomotor disorders,
nutritional assessment,
the MMSE Cognitive Function Evaluation Questionnaire,
the GDS-4 mood rating scale,
the comorbidity assessment test (Charlson Index)</description>
    <arm_group_label>Inoperable squamous cell cancer of the head and neck</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 70 years of age or older with ENT carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject aged 70 or over

          -  Carrier of squamous cell carcinoma of the head and neck, locally advanced undergoing
             treatment by radiotherapy or metastatic / recurrence not accessible to treatment
             curative locoregional under treatment with chemotherapy.

          -  Patient likely to be eligible for ELAN-RT or ELAN-FIT or ELAN-UNFIT trials.

          -  Patients affiliated to a social security scheme

        Exclusion Criteria:

          -  Person deprived of liberty or under guardianship,

          -  Presence of a neuro-psychological condition, family, social, or geographical, which
             may hinder the smooth running of the study.

          -  Patient expressing opposition to participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Joel GUIGAY, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joel GUIGAY, MD, PhD</last_name>
    <phone>0492031501</phone>
    <phone_ext>+33</phone_ext>
    <email>joel.guigay@nice.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CÃ©cile MERTENS, MD</last_name>
    <phone>0556337828</phone>
    <phone_ext>+33</phone_ext>
    <email>C.Mertens@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne AUPERIN, MD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>anne.auperin@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

